Common reasons for denial include income limits, missing documents, or insurance status
If you have a BMI over 30, or over 27 with a weight-related health condition, you may qualify for Wegovy or Mounjaro under current prescribing guidelines
(Both Hims & Hers and Noom, a weight-management company, advocated before the vote for peptides to be allowed to be made at compounding pharmacies.) What did the committee decide
Common side effects include nausea, diarrhea and constipation, which typically subside as the body adjusts to the medication." Laura Buford, MD Importantly, GLP-1 medications only temporarily affect gastric emptying while you are actively taking them
The nature of the suppression is worth describing because it differs from what most people expect
A 2021 review of 13 studies reached a similar conclusion, finding that GLP-1 receptor agonist treatment caused between 11.2 to 13.6 pounds of weight loss over periods ranging from 12 to 68 weeks